Just a moment, the page is loading...

*EISAI-E7080-J081-103




An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors
lenvatinib
E7080-J081-103
NCT00280397
Solid Tumors
Phase 1
 
Analysis and reporting datasets are not CDISC compliant and contain labelling in English and Japanese. Note: Japan is the only country participating in this study.
September 2015